While I share your opinion about board members and gravy train's this is an interesting development.
Insulet ($PODD) has a contract with Amgen to supply a wearable device for Nuelasta. Additionally Orbimed was invested in PODD up until August of last year prior to the commencement of the strategic review which ended up with Amgen becoming a strategic partner. This appointment adds depth with someone who has practical knowledge of the wearable space both for biologic delivery and insulin delivery.
Aditionally $PODD is owned almost entirely by the big institutional guys so this guy is well know on the street.
https://www.medtechintelligence.com...-insulet-explores-viable-smart-drug-delivery/
Additionally don't forget Insulet also makes a wearable insulin pump for type I diabetes.
IMO he was a good get.
